Entry Point Capital, LLC Moon Lake Immunotherapeutics Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
Shares
2 transactions
Others Institutions Holding MLTX
# of Institutions
137Shares Held
58.1MCall Options Held
124KPut Options Held
96.9K-
Bvf Inc San Francisco, CA19.8MShares$792 Million39.28% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$341 Million35.64% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.34MShares$134 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$111 Million2.15% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.19MShares$87.7 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.48B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...